2-甲基-4-(氯甲基)吡啶 | 75523-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-4-(氯甲基)吡啶
• 英文名称: 4-(chloromethyl)-2-methylpyridine
• 英文别名: 2-methyl-pyridin-4-ylmethyl chloride
• CAS: 75523-42-1
• 化学式: C₇H₈ClN
• 分子量: 141.6
• InChiKey: XDDLZDABUCJCMO-UHFFFAOYSA-N

物化性质

• 沸点：
  218℃
• 密度：
  1.118
• 闪点：
  106℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-甲基-4-(氯甲基)吡啶 在 platinum(IV) oxide 硫酸 、 氢气 、 sodium hydride 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 生成 ((2S,4R,6S)-2-Carbamoyl-6-methyl-piperidin-4-ylmethyl)-phosphonic acid diethyl ester
  参考文献：
  名称：

  4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors and anticonvulsant activity

  摘要：

  A series of 4-(phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids were synthesized, and their biological activity was assessed as competitive ligands for the NMDA receptor, both in vitro by using a receptor binding assay ([3H]CGS 19755 binding) and in vivo by using an NMDA seizure model in mice. The analogues were also evaluated in [3H]AMPA and [3H]kainate binding to assess their affinity for non-NMDA excitatory amino acid receptor subtypes. A number of these analogues show potent and selective NMDA antagonistic activity both in vitro and in vivo. Most notable are 4-(phosphonomethyl)-2-piperidinecarboxylic acid (1a) (CGS 19755) and the phosphonopropenyl analogue 1i, both of which show anticonvulsant activity in the 1-2 mg/kg ip range. With the aid of computer-assisted modeling, a putative bioactive conformation for AP-5 is hypothesized from the SAR data presented and a preliminary model for the antagonist-preferring state of the NMDA receptor is presented.

  DOI：

  10.1021/jm00129a025
• 作为产物：
  描述：

  2,4-二甲基吡啶 1-氧化物 在 乙酸酐 、 三氯化磷 、 苯 作用下， 生成 2-甲基-4-(氯甲基)吡啶
  参考文献：
  名称：

  Furukawa, Pharmaceutical Bulletin, 1955, vol. 3, p. 413,415

  摘要：

  DOI：

文献信息

• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• [EN] NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS<br/>[FR] NOUVEAUX COMPOSÉS DE TÉTRAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DE LA TUBERCULOSE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019034729A1

  公开（公告）日：2019-02-21

  The invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.

  这项发明涉及到式（I）的化合物或其药用盐以及它们在治疗中的应用，例如在治疗分枝杆菌感染或治疗由分枝杆菌引起的疾病，如结核病。
• MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF
  申请人：Foresee Pharmaceuticals Co., Ltd.

  公开号：US20190352288A1

  公开（公告）日：2019-11-21

  Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

  基于海达通的化合物对基质金属蛋白酶（MMPs）有抑制作用，尤其是巨噬细胞弹性蛋白酶（MMP-12）。本文还描述了相关的组合物及使用这些化合物抑制MMP-12和治疗由MMP-12介导的疾病的方法，如哮喘、慢性阻塞性肺病（COPD）、肺气肿、急性肺损伤、特发性肺纤维化（IPF）、结节病、系统性硬化病、肝纤维化、非酒精性脂肪肝炎（NASH）、关节炎、癌症、心脏病、炎症性肠病（IBD）、急性肾损伤（AKI）、慢性肾病（CKD）、阿尔波特综合症和肾炎。
• [EN] PROCESS FOR PREPARATION OF OPTICALLY ENRICHED ISOXAZOLINES<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ISOXAZOLINES OPTIQUEMENT ENRICHIES
  申请人：BASF SE

  公开号：WO2021197880A1

  公开（公告）日：2021-10-07

  The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I), formula (I), wherein the variables are as defined in the specification, and the shown enantiomer has at least 55% ee; by oxo-Michael addition of hydroxyl amine or its salt to an enone of formula (II), formula (II), wherein the variables have the meanings given for formula (I), in the presence of a catalyst of formula (III), formula (III), and a base, the invention furthermore relates to novel compounds of formula (III).

  本发明涉及一种用于制备光学富集异恶唑啉化合物公式（I）的过程，公式（I），其中变量如说明书中所定义，并且所示对映体至少具有55%的ee；通过羟基胺或其盐的氧代-Michael加成到公式（II）的烯酮上，公式（II），其中变量具有如公式（I）所给出的含义，在公式（III）的催化剂和碱的存在下，本发明还涉及新型公式（III）的化合物。
• Benzothiazole derivatives with activity as adenosine receptor ligands
  申请人：——

  公开号：US20020045615A1

  公开（公告）日：2002-04-18

  The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.

  本发明涉及替代苯并噻唑衍生物及其药用可接受的盐，用于治疗与腺苷受体相关的疾病。